A PCV specifically designed for adults that helps protect against the serotypes responsible for the most cases of adult IPD1,2,a
THAT’S BRILLIANT DESIGN
Percentage of IPD cases caused by serotypes covered by CAPVAXIVE vs PCV20 among adults aged 50+ years at a national level1,2,a,b
% of IPD cases in adults 50+ covered by vaccine serotypes
CAPVAXIVE is the only FDA-approved pneumococcal conjugate vaccine that helps protect against serotypes responsible for ~82% of invasive pneumococcal disease cases in adults 50 years or older, compared to ~54% by PCV20 on a national level.1,2,a Learn more >>
Intentional serotype selection1,2,b
CAPVAXIVE is specifically designed to help protect against the serotypes responsible for the most cases of adult IPD.
11 serotypes in CAPVAXIVE
that are not covered by PCV20 cause
~37% of IPD cases
in adults 50 years or older at a national level.
9 serotypes in PCV20
that are not covered by CAPVAXIVE cause
~8% of IPD cases
in the same age group.
These values are based on CDC epidemiologic data and do not reflect the efficacy of the respective vaccines.2 There are currently no studies comparing the efficacy of CAPVAXIVE and PCV20.
Quick links:
CDC recommendations
Dosing and administration
Reimbursement
CDC recommendations: updated October 20243
*Routine if PCV13 was administered at any age and PPSV23 was administered before age 65 with the last pneumococcal vaccine being at least 5 years prior. Shared clinical decision-making if PCV13 was administered at any age and PPSV23 was administered at or after the age of 65 and the last pneumococcal vaccine was at least 5 years prior.3
†Certain chronic medical conditions (eg, diabetes, chronic heart disease, chronic lung disease, or chronic liver disease) or behavioral risk factors (eg, smoking or alcoholism).3
‡See ACIP recommendations for full list of immunocompromising conditions, including HIV.3
§Also applies to patients with certain immunocompromising conditions who have received PCV13 followed by 2 doses of PPSV23.3
Are my adult patients at risk?
Learn about the burden of disease and how your patients might be affected.
Share with health care professionals
aBased on CDC ABC surveillance data from the years 2019–2023, representing ~35 million persons and 10 states across the US. Regional variations may exist.2,3,5-9
bPCV20 serotypes for IPD case coverage: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.10
CAPVAXIVE serotypes for IPD case coverage: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
ABC, Active Bacterial Core; ACIP, Advisory Committee on Immunization Practices; CDC, Centers for Disease Control and Prevention; CSF, cerebrospinal fluid; FDA, Food and Drug Administration; HIV, human immunodeficiency virus; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PCV15, 15-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; US, United States.
References:
- ABCs bact facts interactive data dashboard. SPN serotypes 1998-2023. Centers for Disease Control and Prevention. August 21, 2025. Accessed August 27, 2025. https://www.cdc.gov/abcs/bact-facts/data-dashboard.html
- 1998-2023 serotype data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance. Centers for Disease Control and Prevention. Updated November 14, 2025. Accessed November 20, 2025. https://data.cdc.gov/Public-Health-Surveillance/1998-2023-Serotype-Data-for-Invasive-Pneumococcal-/qvzb-qs6p/about_data
- Kobayashi M, Leidner AJ, Gierke R, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8. doi:10.15585/mmwr.mm7401a1
- Data available on request from Merck National Service Center via email at daprequests@merck.com. Please specify information package US-PVV-01008.
- Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2019. Centers for Disease Control and Prevention. Updated June 16, 2021. Accessed August 1, 2025. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf
- Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2020. Centers for Disease Control and Prevention. Updated September 20, 2022. Accessed August 1, 2025. https://stacks.cdc.gov/view/cdc/140328
- Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2021. Centers for Disease Control and Prevention. Updated June 2, 2023. Accessed August 4, 2025. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2021.pdf
- Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2022. Centers for Disease Control and Prevention. Updated July 5, 2024. Accessed August 1, 2025. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2022.pdf
- Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2023. Centers for Disease Control and Prevention. Updated March 20, 2025. Accessed July 28, 2025. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2023.pdf
- Prevnar 20. Prescribing Information. Pfizer Inc; 2023.